explore -WSS

explore

author：Wikipedia 2025-09-28 23:47:06 - browse：5987

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Experts study whether long Covid risk adds up with each reinfection

WSS

Mom launches Girl Scout troop for LGBTQ youth in Texas

How to fix the rural physician shortage in the U.S.

Ukraine and a new approach to mental health in war

Ukraine and a new approach to mental health in war

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Eli Lilly’s Mounjaro succeeds in second weight

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why are Kaiser Permanente staff considering a strike?

Affirmative action in medical school literally saved lives

Mom launches Girl Scout troop for LGBTQ youth in Texas

Walensky prepares to leave CDC — and Congress — behind

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ukraine and a new approach to mental health in war

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Reanimated hearts work just as well for transplants, study finds

explore

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Medical student insurance fails on mental health care coverage

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Millions may soon lose Medicaid when they don't have to

It's been 20 years since Dolly the sheep. Where's my clone?

hotspot

knowledge

knowledge

Wikipedia